{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:21:08Z","timestamp":1787739668936,"version":"build-2784847793"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI132323"],"award-info":[{"award-number":["1R01AI132323"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM103516"],"award-info":[{"award-number":["P30GM103516"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008782","name":"University of Hawai'i","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.vaccine.2025.127684","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T02:47:38Z","timestamp":1756781258000},"page":"127684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Thermostable bivalent &amp; trivalent filovirus vaccines from insect cells: potency demonstrated after 3\u00a0months and 2\u00a0years"],"prefix":"10.1016","volume":"64","author":[{"given":"Ludwig I.","family":"Mayerlen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri Ann S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanore","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreola","family":"Donini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel T.","family":"Lehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127684_bb0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcv.2015.01.014","article-title":"Ebola and Marburg haemorrhagic fever","volume":"64","author":"Rougeron","year":"2015","journal-title":"J. Clin. Virol."},{"issue":"6","key":"10.1016\/j.vaccine.2025.127684_bb0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/8755122520950692","article-title":"Ervebo (Ebola Zaire vaccine, live\/rVSV\u0394G-ZEBOV-GP): the first licensed vaccine for the prevention of Ebola virus disease","volume":"36","author":"Piszczatoski","year":"2020","journal-title":"J Pharmacy Technol"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127684_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010078","article-title":"Current state of Ebola virus vaccines: a snapshot","volume":"17","author":"Woolsey","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2025.127684_bb0020","author":"CDC"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127684_bb0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/humc.2018.129","article-title":"Establishing China\u2019s National Standard for the recombinant adenovirus type 5 vector-based Ebola vaccine (Ad5-EBOV) virus Titer","volume":"29","author":"Li","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.vaccine.2025.127684_bb0030","series-title":"European Medicines Agency","article-title":"Zabdeno","author":"EMA","year":"2020"},{"key":"10.1016\/j.vaccine.2025.127684_bb0035","series-title":"Mvabea","author":"EMA","year":"2020"},{"key":"10.1016\/j.vaccine.2025.127684_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.703986","article-title":"Recombinant protein filovirus vaccines protect Cynomolgus macaques from Ebola, Sudan, and Marburg viruses","volume":"12","author":"Lehrer","year":"2021","journal-title":"Front. Immunol."},{"issue":"6972","key":"10.1016\/j.vaccine.2025.127684_bb0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature02165","article-title":"Structure of the dengue virus envelope protein after membrane fusion","volume":"427","author":"Modis","year":"2004","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127684_bb0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1750-2659.2008.00053.x","article-title":"FluBlok, a recombinant hemagglutinin influenza vaccine","volume":"2","author":"Cox","year":"2008","journal-title":"Influenza Other Respir. Viruses"},{"issue":"31","key":"10.1016\/j.vaccine.2025.127684_bb0055","doi-asserted-by":"crossref","first-page":"10061","DOI":"10.1021\/acs.iecr.8b00985","article-title":"The coming age of insect cells for manufacturing and development of protein therapeutics","volume":"57","author":"Yee","year":"2018","journal-title":"Ind. Eng. Chem. Res."},{"key":"10.1016\/j.vaccine.2025.127684_bb0060","series-title":"Novavax\u2019s NuvaxovidTM receives full marketing authorization in the EU for the prevention of COVID","author":"Novavax","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127684_bb0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/978-1-0716-0795-4_27","article-title":"Thin-film freeze-drying is a viable method to convert vaccines containing Aluminum salts from liquid to dry powder","volume":"2183","author":"Alzhrani","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.vaccine.2025.127684_bb0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2021.01.016","article-title":"Stability of lyophilized and spray dried vaccine formulations","volume":"171","author":"Preston","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.vaccine.2025.127684_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121637","article-title":"Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying","volume":"618","author":"Hufnagel","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.vaccine.2025.127684_bb0080","first-page":"223","article-title":"Lyophilization of vaccines: current trends","volume":"87","author":"Adams","year":"2003","journal-title":"Methods Mol Med"},{"issue":"46","key":"10.1016\/j.vaccine.2025.127684_bb0085","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1016\/j.vaccine.2018.10.023","article-title":"Physical and chemical changes in Alhydrogel damaged by freezing","volume":"36","author":"Kurzatkowski","year":"2018","journal-title":"Vaccine"},{"issue":"39","key":"10.1016\/j.vaccine.2025.127684_bb0090","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1016\/j.vaccine.2021.08.003","article-title":"Single-vial filovirus glycoprotein vaccines: biophysical characteristics and immunogenicity after co-lyophilization with adjuvant","volume":"39","author":"Preston","year":"2021","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127684_bb0095","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.vaccine.2023.12.053","article-title":"Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection","volume":"42","author":"To, A","year":"2024","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127684_bb0100","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.xphs.2020.09.011","article-title":"Preservation of quaternary structure in thermostable, lyophilized filovirus glycoprotein vaccines: a search for stability-indicating assays","volume":"109","author":"Preston","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.vaccine.2025.127684_bb0105","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1016\/j.xphs.2022.05.017","article-title":"Lyophilized filovirus glycoprotein vaccines: peroxides in a vaccine formulation with polysorbate 80-containing adjuvant are associated with reduced neutralizing antibody Titers in both mice and non-human Primates","volume":"111","author":"Preston","year":"2022","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.vaccine.2025.127684_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007614","article-title":"Serological evidence of Ebola virus exposure in dogs from affected communities in Liberia: a preliminary report","volume":"13","author":"Haun","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.vaccine.2025.127684_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2021.100126","article-title":"Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice","volume":"9","author":"Lai","year":"2021","journal-title":"Vaccine X"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127684_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/v14122784","article-title":"Maternal immunization using a protein subunit vaccine mediates passive immunity against Zaire ebolavirus in a murine model","volume":"14","author":"Williams","year":"2022","journal-title":"Viruses"},{"issue":"22","key":"10.1016\/j.vaccine.2025.127684_bb0125","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.vaccine.2017.01.068","article-title":"Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice","volume":"36","author":"Lehrer","year":"2018","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.vaccine.2025.127684_bb0130","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1016\/j.vaccine.2019.06.035","article-title":"Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge","volume":"37","author":"Lehrer","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127684_bb0135","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejpb.2019.01.019","article-title":"Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide","volume":"136","author":"Chisholm","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:51:23Z","timestamp":1769025083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25009818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"alternative-id":["S0264410X25009818"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127684","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3\u00a0months and 2\u00a0years","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127684"}}